

Seiji Yano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5339601/publications.pdf>

Version: 2024-02-01

92
papers

3,596
citations

201575

27
h-index

143943

57
g-index

96
all docs

96
docs citations

96
times ranked

4924
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab. <i>Internal Medicine</i> , 2022, 61, 75-79.	0.3	0
2	Multi-institutional survey of thymic carcinoma patients in Hokushin region. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 419-424.	1.2	4
3	Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1153-1158.	1.2	1
4	Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. <i>Internal Medicine</i> , 2022, 61, 1735-1738.	0.3	3
5	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring <i>EGFR</i>â€”790M mutation in nonâ€”small cell lung cancer cells. <i>Cancer Medicine</i> , 2022, 11, 944-955.	1.3	5
6	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. <i>Npj Precision Oncology</i> , 2022, 6, 5.	2.3	13
7	A Case of Methicillin-resistant “Staphylococcus aureus“ Necrotizing Bronchitis after Radiotherapy in Combination with Axitinib. <i>Internal Medicine</i> , 2022, , .	0.3	1
8	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. <i>Npj Precision Oncology</i> , 2022, 6, 11.	2.3	8
9	Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of <i>NTRK1</i>â€”rearranged tumor cells. <i>Cancer Science</i> , 2022, 113, 2323-2335.	1.7	5
10	Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer. <i>Biochemical and Biophysical Research Communications</i> , 2022, 600, 80-86.	1.0	2
11	Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 378-383.	0.3	1
12	Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression. <i>Clinical Cancer Research</i> , 2021, 27, 1410-1420.	3.2	24
13	Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy. <i>In Vivo</i> , 2021, 35, 401-410.	0.6	5
14	Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2503-2515.	2.0	28
15	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass. <i>Internal Medicine</i> , 2021, 60, 409-415.	0.3	1
16	Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1009-1014.	1.0	6
17	Androgen replacement therapy for cancerâ€”related symptoms in male: result of prospective randomized trial (ARTFORM study). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 831-842.	2.9	6
18	TGF-â€”2-dependent reprogramming of amino acid metabolism induces epithelialâ€”mesenchymal transition in non-small cell lung cancers. <i>Communications Biology</i> , 2021, 4, 782.	2.0	29

#	ARTICLE	IF	CITATIONS
19	Trametinib overcomes KRAS ^{G12V} -induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. <i>Cancer Science</i> , 2021, 112, 3784-3795.	1.7	12
20	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	1.3	12
21	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 522, 119-128.	3.2	13
22	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325.	1.3	13
23	Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. <i>Japanese Journal of Clinical Oncology</i> , 2021, , .	0.6	3
24	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146.	0.9	32
25	The Brain Microenvironment Induces DNMT1 Suppression and Indolence of Metastatic Cancer Cells. <i>IScience</i> , 2020, 23, 101480.	1.9	17
26	Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8904.	1.8	16
27	In Reply. <i>Journal of Thoracic Oncology</i> , 2020, 15, e93.	0.5	0
28	Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion. <i>Scientific Reports</i> , 2020, 10, 16678.	1.6	6
29	MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. <i>Cancer Science</i> , 2020, 111, 3813-3823.	1.7	9
30	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69
31	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. <i>BMC Cancer</i> , 2020, 20, 156.	1.1	6
32	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 752-765.	0.5	24
33	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256.	3.2	75
34	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. <i>Trials</i> , 2020, 21, 298.	0.7	6
35	Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa116.	0.2	2
36	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. <i>Cancer Science</i> , 2020, 111, 561-570.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. <i>Cancer Science</i> , 2020, 111, 2374-2384.	1.7	17
38	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM; deletion polymorphism. <i>Journal of Medical Investigation</i> , 2020, 67, 343-350.	0.2	3
39	Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. <i>Anticancer Research</i> , 2019, 39, 3871-3878.	0.5	23
40	Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases. <i>Anticancer Research</i> , 2019, 39, 5449-5459.	0.5	6
41	Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. <i>Cancer Science</i> , 2019, 110, 3215-3224.	1.7	32
42	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 947-956.	1.9	14
43	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. <i>Cancer Research</i> , 2019, 79, 1658-1670.	0.4	79
44	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. <i>Molecular Cancer</i> , 2019, 18, 165.	7.9	160
45	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	5.8	223
46	Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. <i>Oncogene</i> , 2019, 38, 2464-2481.	2.6	75
47	Caput Medusae-like Venous Dilatation in Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3341-3342.	0.3	2
48	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018, 24, 2357-2369.	3.2	25
49	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. <i>Oncogene</i> , 2018, 37, 1775-1787.	2.6	28
50	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 17-25.	1.9	37
51	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 193.	0.8	12
52	Notch3-dependent β -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. <i>Nature Communications</i> , 2018, 9, 3198.	5.8	61
53	Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017, 108, 53-60.	1.7	28
54	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 506-515.	1.9	52

#	ARTICLE	IF	CITATIONS
55	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. <i>Cancer Science</i> , 2017, 108, 696-703.	1.7	15
56	Impact of <sc>MET</sc> inhibition on smallâ€cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/<sc>MET</sc> pathway. <i>Cancer Science</i> , 2017, 108, 1378-1385.	1.7	20
57	Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphismâ€Mediated Osimertinib Resistance in <i>EGFR</i> Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3139-3149.	3.2	69
58	Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. <i>Carcinogenesis</i> , 2017, 38, 1063-1072.	1.3	16
59	<i>In vivo</i> imaging xenograft models for the evaluation of antiâ€brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , 2017, 6, 2972-2983.	1.3	2
60	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 317-320.	0.2	16
61	Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). <i>Journal of Medical Investigation</i> , 2017, 64, 202-204.	0.2	2
62	Phase I study of combined therapy with vorinostat and gefitinib to treat <i>BIM</i> deletion polymorphism-associated resistance in <i>EGFR</i>-mutant lung cancer (VICTROY-J): a study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 321-325.	0.2	7
63	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	0.8	13
64	<i>In vitro</i> and <i>in vivo</i> anti-tumor activity of alectinib in tumor cells with NCOA4-RET. <i>Oncotarget</i> , 2017, 8, 73766-73773.	0.8	10
65	Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2016, 2, 15.	0.4	7
66	Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i>-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 754-769.	7.7	132
67	Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. <i>Molecular and Clinical Oncology</i> , 2016, 4, 537-540.	0.4	1
68	Recent trends of cancer treatment by targeted drugs. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2016, 25, 259-263.	0.0	0
69	Organâ€specific efficacy of <sc>HSP</sc>90 inhibitor in multipleâ€organ metastasis model of chemorefractory small cell lung cancer. <i>International Journal of Cancer</i> , 2016, 138, 1281-1289.	2.3	14
70	Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. <i>Journal of Biochemistry</i> , 2016, 160, 227-232.	0.9	13
71	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells. <i>Oncotarget</i> , 2016, 7, 3847-3856.	0.8	56
72	Biomarkers for Lung Cancer: Focusing on Targeted Drug Resistance. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 55-60.	0.0	0

#	ARTICLE	IF	CITATIONS
73	TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 121-7.	0.5	12
74	Elevated β -catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. <i>Scientific Reports</i> , 2015, 5, 13076.	1.6	40
75	Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. <i>Nature Communications</i> , 2015, 6, 8792.	5.8	57
76	<i>In vivo</i> imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. <i>Cancer Science</i> , 2015, 106, 244-252.	1.7	32
77	Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. <i>Nature Communications</i> , 2015, 6, 7679.	5.8	106
78	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. <i>Cancer Research</i> , 2015, 75, 4188-4197.	0.4	16
79	Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance. <i>Respiratory Investigation</i> , 2014, 52, 348-356.	0.9	15
80	The Current State of Molecularly Targeted Drugs Targeting HGF/Met. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 9-12.	0.6	25
81	Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. <i>Oncology Reports</i> , 2014, 31, 1109-1115.	1.2	12
82	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014, 5, 4920-4928.	0.8	46
83	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. <i>Cancer Research</i> , 2013, 73, 2428-2434.	0.4	151
84	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. <i>PLoS ONE</i> , 2013, 8, e84700.	1.1	41
85	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1663-1671.	3.2	81
86	Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. <i>Cancer Science</i> , 2012, 103, 1189-1194.	1.7	64
87	Antiangiogenic therapies for malignant pleural mesothelioma. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 740.	3.0	6
88	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2011-2017.	0.5	196
89	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 6630-6638.	3.2	255
90	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. <i>Cancer Research</i> , 2008, 68, 9479-9487.	0.4	574

#	ARTICLE	IF	CITATIONS
91	Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice. <i>Clinical Cancer Research</i> , 2005, 11, 8789-8798.	3.2	45
92	Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. , 1996, 67, 211-217.		64